Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Importance: Sexual minority (SM) persons have been found to have differential rates of skin cancer, but limited data exist on differences across racial and ethnic groups and by individual sexual identities.

Objective: To examine differences by sexual orientation in the lifetime prevalence of skin cancer among US adult females and males across racial and ethnic groups and by individual sexual identity.

Design, Setting, And Participants: This cross-sectional study used data from the Behavioral Risk Factor Surveillance System from January 1, 2014, to December 31, 2021, for US adults from the general population. Data were analyzed from December 1, 2023, to March 1, 2024.

Main Outcomes And Measures: Self-reported lifetime prevalence of skin cancer by sexual orientation. Age-adjusted prevalence and adjusted prevalence odds ratios (AORs) compared heterosexual and SM adults in analyses stratified by individual race.

Results: Of 1 512 400 participants studied, 805 161 (53.2%) were heterosexual females; 38 933 (2.6%), SM females; 638 651 (42.2%), heterosexual males; and 29 655 (2.0%), SM males. A total of 6.6% of participants were Hispanic; 3.4%, non-Hispanic Asian, Pacific Islander, or Hawaiian; 7.5%, non-Hispanic Black; 78.2%, non-Hispanic White; and 4.3%, other race and ethnicity. Mean (SE) age was 48.5 (0.03) years (incomplete data for age of respondents ≥80 years). The lifetime prevalence of skin cancer was overall higher among SM males compared with heterosexual males (7.4% vs 6.8%; AOR, 1.16; 95% CI, 1.02-1.33), including specifically among Hispanic males (4.0% vs 1.6%; AOR, 3.81; 95% CI, 1.96-7.41) and non-Hispanic Black males (1.0% vs 0.5%; AOR, 2.18; 95% CI, 1.13-4.19) in analyses stratified by race and ethnicity. Lifetime prevalence rates were lower among SM females compared with heterosexual females among non-Hispanic White females (7.8% vs 8.5%; AOR, 0.86; 95% CI, 0.76-0.97) and were higher among Hispanic (2.1% vs 1.8%; AOR, 2.46; 95% CI, 1.28-4.70) and non-Hispanic Black (1.8% vs 0.5%; AOR, 2.33; 95% CI, 1.01-5.54) females in analyses stratified by race and ethnicity.

Conclusions And Relevance: In this cross-sectional study of US adults, differences in the lifetime prevalence of skin cancer among SM adults compared with heterosexual adults differed across racial and ethnic groups and by individual sexual identity among both females and males. Both Hispanic and non-Hispanic Black and SM females and males had higher rates of skin cancer compared with their heterosexual counterparts. Further research addressing the individual factors contributing to these differences is needed to inform screening guidelines and public health interventions focused on these diverse, heterogeneous populations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11255965PMC
http://dx.doi.org/10.1001/jamadermatol.2024.2097DOI Listing

Publication Analysis

Top Keywords

skin cancer
28
lifetime prevalence
24
prevalence skin
20
compared heterosexual
20
racial ethnic
16
ethnic groups
16
non-hispanic black
16
sexual orientation
12
groups individual
12
individual sexual
12

Similar Publications

Letter to the editor: Clarifying skin cancer definitions and time frames in liver transplant recipients.

Liver Transpl

September 2025

Department of Anesthesiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102218, China.

View Article and Find Full Text PDF

Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.

Methods: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib.

View Article and Find Full Text PDF

Background: With the increasing incidence of skin cancer, the workload for pathologists has surged. The diagnosis of skin samples, especially for complex lesions such as malignant melanomas and melanocytic lesions, has shown higher diagnostic variability compared to other organ samples. Consequently, artificial intelligence (AI)-based diagnostic assistance programs are increasingly needed to support dermatopathologists in achieving more consistent diagnoses.

View Article and Find Full Text PDF

Managing moderate-to-severe psoriasis in patients with current or past malignancy remains a therapeutic challenge. We conducted a multicentre, retrospective real-world study to assess the safety and effectiveness of guselkumab in this complex population. Thirty patients were included, of whom 11 had active cancer at the time of guselkumab initiation.

View Article and Find Full Text PDF

Zosteriform Primary Cutaneous Marginal Zone Lymphoma-A Case Report.

Australas J Dermatol

September 2025

Sydney School of Medicine, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.

We report a case of zosteriform PCMZL presenting in a T3-T4 dermatomal distribution not previously described in the literature. Although the varicella zoster virus was not detected in this case, late diagnosis of the acute eruption of zoster or even preceding zoster 'sine herpete' cannot be excluded as antigenic triggers.

View Article and Find Full Text PDF